Boronic acid inhibitors of penicillin-binding protein 1b: serine and lysine labelling agents

References

• Neil JO. Report on antimicrobial resistance. 2016. https://amr-review.org/.
   Google Scholar
• Ventola CL. The antibiotic resistance crisis, part 1: causes and threats. Pharm Ther. 2015;40(4):277–283.
   Google Scholar
• Ventola CL. The antibiotic resistance crisis, part 2: management strategies and new agents. Pharm Ther. 2015;40(5):344–352.
   Google Scholar
• O'Rourke A, Beyhan S, Choi Y, Morales P, Chan AP, Espinoza JL, Dupont CL, Meyer KJ, Spoering A, Lewis K, et al. Mechanism-of-action classification of antibiotics by global transcriptome profiling. Antimicrob Agents Chemother. 2020;64(3):e01207–19.
   PubMed Web of Science ®Google Scholar
• Zaman SB, Hussain MA, Nye R, Mehta V, Mamun KT, Hossain N. A review on antibiotic resistance: alarm bells are ringing. Cureus. 2017;9(6):e1403.
   PubMed Web of Science ®Google Scholar
• Sarkar P, Yarlagadda V, Ghosh C, Haldar J. A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics. Medchemcomm. 2017;8(3):516–533.
   PubMed Web of Science ®Google Scholar
• Lima LM, Silva B. d, Barbosa G, Barreiro EJ. β-lactam antibiotics: an overview from a medicinal chemistry perspective. Eur J Med Chem. 2020;208:112829.
   PubMed Web of Science ®Google Scholar
• Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev. 2008;32(2):234–258.
   PubMed Web of Science ®Google Scholar
• Matteï PJ, Neves D, Dessen A. Bridging cell wall biosynthesis and bacterial morphogenesis. Curr Opin Struct Biol. 2010;20(6):749–755.
   PubMed Web of Science ®Google Scholar
• Ghuysen JM. Use of bacteriolytic enzymes in determination of wall structure and their role in cell metabolism. Bacteriol Rev. 1968;32(4 Pt 2):425–464.
   PubMedGoogle Scholar
• Schleifer KH, Kandler O. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol Rev. 1972;36(4):407–477.
   PubMedGoogle Scholar
• Born P, Breukink E, Vollmer W. In vitro synthesis of cross-linked murein and its attachment to sacculi by PBP1A from Escherichia coli. J Biol Chem. 2006;281(37):26985–26993.
   PubMed Web of Science ®Google Scholar
• Macheboeuf P, Contreras-Martel C, Job V, Dideberg O, Dessen A. Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes. FEMS Microbiol Rev. 2006;30(5):673–691.
   PubMed Web of Science ®Google Scholar
• Popham DL, Gilmore ME, Setlow P. Roles of low-molecular-weight penicillin-binding proteins in Bacillus subtilis spore peptidoglycan synthesis and spore properties. J Bacteriol. 1999;181(1):126–132.
   PubMed Web of Science ®Google Scholar
• Sauvage E, Terrak M. Glycosyltransferases and transpeptidases/penicillin-binding proteins: valuable targets for new antibacterials. Antibiotics. 2016;5(1):12.
   Google Scholar
• Meberg BM, Sailer FC, Nelson DE, Young KD. Reconstruction of Escherichia coli mrcA (PBP1a) mutants lacking multiple combinations of penicillin binding proteins. J Bacteriol. 2001;183(20):6148–6149.
   PubMed Web of Science ®Google Scholar
• Denome SA, Elf PK, Henderson TA, Nelson DE, Young KD. Escherichia coli mutants lacking all possible combinations of eight penicillin binding proteins: viability, characteristics, and implications for peptidoglycan synthesis. J Bacteriol. 1999;181(13):3981–3993.
   PubMed Web of Science ®Google Scholar
• Inglis SR, Strieker M, Rydzik AM, Dessen A, Schofield CJ. A boronic-acid-based probe for fluorescence polarization assays with penicillin binding proteins and β-lactamases. Anal Biochem. 2012;420(1):41–47.
   PubMed Web of Science ®Google Scholar
• Tipper DJ, Strominger JL. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc Natl Acad Sci USA. 1965;54(4):1133–1141.
   PubMed Web of Science ®Google Scholar
• Tang SS, Apisarnthanarak A, Hsu LY. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Adv Drug Deliv Rev. 2014;78:3–13.
   PubMed Web of Science ®Google Scholar
• Péczka N, Orgován Z, Ábrányi-Balogh P, Keserű GM. Electrophilic warheads in covalent drug discovery: an overview. Expert Opin Drug Discov. 2022;17(4):413–422.
   PubMed Web of Science ®Google Scholar
• Yang W, Gao X, Wang B. Boronic acid compounds as potential pharmaceutical agents. Med Res Rev. 2003;23(3):346–368.
   PubMed Web of Science ®Google Scholar
• Silva MP, Saraiva L, Pinto M, Sousa ME. Boronic acids and their derivatives in medicinal chemistry: synthesis and biological applications. Molecules. 2020;25(18):4323.
   PubMed Web of Science ®Google Scholar
• Al-Omari MK, Elaarag M, Al-Zoubi RM, Al-Qudimat AR, Zarour AA, Al-Hurani EA, Fares ZE, Alkharraz LM, Shkoor M, Bani-Yaseen AD. Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope. J Enzyme Inhib Med Chem. 2023;38(1):2220084.
   PubMed Web of Science ®Google Scholar
• Trippier PC, McGuigan C. Boronic acids in medicinal chemistry: anticancer, antibacterial and antiviral applications. Med Chem Commun. 2010;1(3):183–198.
   Google Scholar
• Kane RC, Farrell AT, Sridhara R, Pazdur R. United states food and drug administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res. 2006;12(10):2955–2960.
   PubMed Web of Science ®Google Scholar
• Shirley M. Ixazomib: first global approval. Drugs. 2016;76(3):405–411.
   PubMed Web of Science ®Google Scholar
• Patel TS, Pogue JM, Mills JP, Kaye KS. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria. Future Microbiol. 2018;13(9):971–983.
   PubMed Web of Science ®Google Scholar
• Markham A. Tavaborole: first global approval. Drugs. 2014;74(13):1555–1558.
   PubMed Web of Science ®Google Scholar
• Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR, Plattner JJ. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett. 2009;19(8):2129–2132.
   PubMed Web of Science ®Google Scholar
• Contreras-Martel C, Amoroso A, Woon ECY, Zervosen A, Inglis S, Martins A, Verlaine O, Rydzik AM, Job V, Luxen A, et al. Structure-guided design of cell wall biosynthesis inhibitors that overcome β-lactam resistance in staphylococcus aureus (MRSA). ACS Chem Biol. 2011;6(9):943–951.
   PubMed Web of Science ®Google Scholar
• Inglis SR, Zervosen A, Woon ECY, Gerards T, Teller N, Fischer DS, Luxen A, Schofield CJ. Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. J Med Chem. 2009;52(19):6097–6106.
   PubMed Web of Science ®Google Scholar
• Woon ECY, Zervosen A, Sauvage E, Simmons KJ, Zivec M, Inglis SR, Fishwick CWG, Gobec S, Charlier P, Luxen A, et al. Structure guided development of potent reversibly binding penicillin binding protein inhibitors. ACS Med Chem Lett. 2011;2(3):219–223.
   PubMed Web of Science ®Google Scholar
• Stefanova ME, Tomberg J, Davies C, Nicholas RA, Gutheil WG. Overexpression and enzymatic characterization of Neisseria gonorrhoeae penicillin-binding protein. Eur J Biochem. 2004;271(1):23–32.
   PubMedGoogle Scholar
• Nicola G, Peddi S, Stefanova M, Nicholas RA, Gutheil WG, Davies C. Crystal structure of Escherichia coli penicillin-binding protein 5 bound to a tripeptide boronic acid inhibitor: a role for Ser-110 in deacylation. Biochemistry. 2005;44(23):8207–8217.
   PubMed Web of Science ®Google Scholar
• Pechenov A, Stefanova ME, Nicholas RA, Peddi S, Gutheil WG. Potential transition state analogue inhibitors for the penicillin-binding proteins. Biochemistry. 2003;42(2):579–588.
   PubMed Web of Science ®Google Scholar
• Zervosen A, Herman R, Kerff F, Herman A, Bouillez A, Prati F, Pratt RF, Frère JM, Joris B, Luxen A, et al. Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin-binding protein. J Am Chem Soc. 2011;133(28):10839–10848.
   PubMed Web of Science ®Google Scholar
• Newman H, Krajnc A, Bellini D, Eyermann CJ, Boyle GA, Paterson NG, McAuley KE, Lesniak R, Gangar M, Von Delft F, et al. High-throughput crystallography reveals boron-containing inhibitors of a penicillin-binding protein with di- and tricovalent binding modes. J Med Chem. 2021;64(15):11379–11394.
   PubMed Web of Science ®Google Scholar
• Kumar V, Viviani SL, Ismail J, Agarwal S, Bonomo RA, van den Akker F. Structural analysis of the boronic acid β-lactamase inhibitor vaborbactam binding to Pseudomonas aeruginosa penicillin-binding protein 3. PLoS One. 2021;16(10):e0258359.
   PubMed Web of Science ®Google Scholar
• MCULE database [accessed 2022 Aug 1]. https://mcule.com/database/.
   Google Scholar
• Macheboeuf P, Di Guilmi AM, Job V, Vernet T, Dideberg O, Dessen A. Active site restructuring regulates ligand recognition in class A penicillin-binding proteins. Proc Natl Acad Sci USA. 2005;102(3):577–582.
   PubMed Web of Science ®Google Scholar
• Macheboeuf P, Fischer DS, Brown T, Zervosen A, Luxen A, Joris B, Dessen A, Schofield CJ. Structural and mechanistic basis of penicillin-binding protein inhibition by lactivicins. Nat Chem Biol. 2007;3(9):565–569. 2007.
   PubMed Web of Science ®Google Scholar
• King DT, Wasney GA, Nosella M, Fong A, Strynadka NCJ, Peter Guengerich F. Structural insights into inhibition of Escherichia coli Penicillin-binding protein 1B. J Biol Chem. 2017;292(3):979–993.
   PubMed Web of Science ®Google Scholar
• Gaulton A, Hersey A, Nowotka M, Bento AP, Chambers J, Mendez D, Mutowo P, Atkinson F, Bellis LJ, Cibrián-Uhalte E, et al. The ChEMBL database in 2017. Nucleic Acids Res. 2017;45(D1):D945–D954.
   PubMed Web of Science ®Google Scholar
• Toledo Warshaviak D, Golan G, Borrelli KW, Zhu K, Kalid O. Structure-based virtual screening approach for discovery of covalently bound ligands. J Chem Inf Model. 2014;54(7):1941–1950.
   PubMed Web of Science ®Google Scholar
• Zhu K, Borrelli KW, Greenwood JR, Day T, Abel R, Farid RS, Harder E. Docking covalent inhibitors: a parameter free approach to pose prediction and scoring. J Chem Inf Model. 2014;54(7):1932–1940.
   PubMed Web of Science ®Google Scholar
• Sun J, Perfetti MT, Santos WL. A method for the deprotection of alkylpinacolyl boronate esters. J Org Chem. 2011;76(9):3571–3575.
   PubMed Web of Science ®Google Scholar
• Dzhekieva L, Adediran SA, Pratt RF. Interactions of “bora-penicilloates” with serine β-lactamases and DD-peptidases. Biochemistry. 2014;53(41):6530–6538.
   PubMed Web of Science ®Google Scholar
• Kishida H, Unzai S, Roper DI, Lloyd A, Park SY, Tame JRH. Crystal structure of penicillin binding protein 4 (dacB) from Escherichia coli, both in the native form and covalently linked to various antibiotics. Biochemistry. 2006;45(3):783–792.
   PubMed Web of Science ®Google Scholar
• Panda N, Mothkuri R. Stereoselective synthesis of enamides by pd-catalyzed hydroamidation of electron deficient terminal alkynes. J Org Chem. 2012;77(20):9407–9412.
   PubMed Web of Science ®Google Scholar
• López A, Clark TB, Parra A, Tortosa M. Copper-catalyzed enantioselective synthesis of β-boron β-amino esters. Org Lett. 2017;19(23):6272–6275.
   PubMed Web of Science ®Google Scholar
• Chatterjee P, Botello-Smith WM, Zhang H, Qian L, Alsamarah A, Kent D, Lacroix JJ, Baudry M, Luo Y. Can relative binding free energy predict selectivity of reversible covalent inhibitors? J Am Chem Soc. 2017;139(49):17945–17952.
   PubMed Web of Science ®Google Scholar
• Contreras-Martel C, Dahout-Gonzalez C, Martins ADS, Kotnik M, Dessen A. PBP active site flexibility as the key mechanism for β-lactam resistance in pneumococci. J Mol Biol. 2009;387(4):899–909.
   PubMed Web of Science ®Google Scholar
• Aguilera Rossi CG, Gómez-Puertas P, Ayala Serrano JA. In vivo functional and molecular characterization of the Penicillin-Binding Protein 4 (DacB) of Pseudomonas aeruginosa. BMC Microbiol. 2016;16(1):234.
   PubMedGoogle Scholar
• Thomas B, Wang Y, Stein RL. Kinetic and mechanistic studies of penicillin-binding protein 2x from Streptococcus pneumoniae. Biochemistry. 2001;40(51):15811–15823.
   PubMed Web of Science ®Google Scholar
• Lu WP, Kincaid E, Sun Y, Bauer MD. Kinetics of β-lactam interactions with Penicillin-susceptible and -resistant Penicillin-binding protein 2x proteins from Streptococcus pneumoniae: involvement of acylation and deacylation in β-lactam resistence. J Biol Chem. 2001;276(34):31494–31501.
   PubMed Web of Science ®Google Scholar
• Shi Q, Meroueh SO, Fisher JF, Mobashery S. A computational evaluation of the mechanism of penicillin-binding protein-catalyzed cross-linking of the bacterial cell wall. J Am Chem Soc. 2011;133(14):5274–5283.
   PubMed Web of Science ®Google Scholar
• Pan AC, Sezer D, Roux B. Finding transition pathways using the string method with swarms of trajectories. J Phys Chem B. 2008;112(11):3432–3440.
   PubMed Web of Science ®Google Scholar
• Akgun B, Hall DG. Boronic acids as bioorthogonal probes for site-selective labeling of proteins. Angew Chem Int Ed Engl. 2018;57(40):13028–13044.
   PubMed Web of Science ®Google Scholar
• Cal PMSD, Vicente JB, Pires E, Coelho AV, Veiros LF, Cordeiro C, Gois PMP. Iminoboronates: a new strategy for reversible protein modification. J Am Chem Soc. 2012;134(24):10299–10305.
   PubMed Web of Science ®Google Scholar
• Reja RM, Wang W, Lyu Y, Haeffner F, Gao J. Lysine-targeting reversible covalent inhibitors with long residence time. J Am Chem Soc. 2022;144(3):1152–1157.
   PubMed Web of Science ®Google Scholar
• Pratt RF. Substrate specificity of bacterial DD-peptidases (penicillin-binding proteins). Cell Mol Life Sci. 2008;65(14):2138–2155.
   PubMed Web of Science ®Google Scholar
• Scarpino A, Ferenczy GG, Keserű GM. Comparative evaluation of covalent docking tools. J Chem Inf Model. 2018;58(7):1441–1458.
   PubMed Web of Science ®Google Scholar
• Hall NE, Smith BJ. Solvation effects on zwitterion formation. J Phys Chem A. 1998;102(22):3985–3990.
   Web of Science ®Google Scholar
• Hall NE, Smith BJ. High-level ab initio molecular orbital calculations of imine formation. J Phys Chem A. 1998;102(25):4930–4938.
   Web of Science ®Google Scholar
• Chan WC, Sharifzadeh S, Buhrlage SJ, Marto JA. Chemoproteomic methods for covalent drug discovery. Chem Soc Rev. 2021;50(15):8361–8381.
   PubMed Web of Science ®Google Scholar
• Plescia J, Moitessier N. Design and discovery of boronic acid drugs. Eur J Med Chem. 2020;195:112270.
   PubMed Web of Science ®Google Scholar
• Petri L, Szijj PA, Kelemen Á, Imre T, Gömöry Á, Lee MTW, Hegedűs K, Ábrányi-Balogh P, Chudasama V, Keserű GM. Cysteine specific bioconjugation with benzyl isothiocyanates. RSC Adv. 2020;10(25):14928–14936.
   PubMed Web of Science ®Google Scholar
• Kollár L, Gobec M, Proj M, Smrdel L, Knez D, Imre T, Gömöry Á, Petri L, Ábrányi-Balogh P, Csányi D, et al. Fragment-sized and bidentate (immuno)proteasome inhibitors erived from cysteine and threonine targeting warheads. Cells. 2021;10(12):3431.
   PubMed Web of Science ®Google Scholar
• Tribello GA, Bonomi M, Branduardi D, Camilloni C, Bussi G. PLUMED 2: new feathers for an old bird. Comput Phys Commun. 2014;185(2):604–613.
   Web of Science ®Google Scholar